ZUPREVO™ 18%

Choose Confidence. Choose Zuprevo.

Zuprevo™ 18% (tildipirosin) is the fast-acting, long-lasting Bovine Respiratory Disease (BRD) treatment you can count on to get the job done. Zuprevo concentrates at the site of the action – in the lungs – to treat BRD.

Controls major BRD-causing bacteria in two ways:
  • Kills Mannheimia haemolytica and Pasteurella multocida
  • Suppresses Mannheimia haemolytica, Pasteurella multocida and Histophilus somni
Convenient, single low-volume dose:
  • 1 mL/100 lbs
  • More doses per bottle
  • Easy to calibrate dose
Highly syringeable over a wide range of temperatures
21-day withdrawal.

See your veterinarian to prescribe new Zuprevo antibiotic to treat BRD and to control respiratory disease in cattle at high risk of developing BRD.


 
Zuprevo 18% (tildipirosin)
Indicated for the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni in beef and non-lactating dairy cattle, and for the control of respiratory disease in beef and non-lactating dairy cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni.

IMPORTANT SAFETY INFORMATION: 

FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. TO AVOIDACCIDENTAL INJECTION, DO NOT USE IN AUTOMATICALLY POWERED SYRINGES WHICH HAVE NOADDITIONAL PROTECTION SYSTEM.IN CASE OF HUMAN INJECTION, SEEK MEDICAL ADVICE IMMEDIATELY AND SHOW THE PACKAGE INSERT OR LABEL TO THE PHYSICIAN.

DO NOT USE Zuprevo 18% IN SWINE. Fatal adverse events have been reported following the use of tildipirosin in swine.

NOT FOR USE IN CHICKENS OR TURKEYS.

Cattle intended for human consumption must not be slaughtered within 21 days of the last treatment. Do not use in female dairy cattle 20 months of age or older. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal.

The effects Zuprevo 18% on bovine reproductive performance, pregnancy and lactation have not been determined. Swelling and inflammation,which may be severe, may be seen at the injection site after administration. Subcutaneous injection may result in local tissue reactions whichpersist beyond slaughter withdrawal period. This may result in trim loss of edible tissue at slaughter.


For complete information, see the product label.
 
PRODUCT LABEL AND MSDS
PRESCRIBING INFORMATION